enVVeno Medical Trading Halted, News Pending
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 17 2026
0mins
enVVeno Medical trading halted, news pending
Get Free Real-Time Notifications for Any Stock
Monitor tickers like NVNO with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on NVNO
About NVNO
enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
enVVeno Medical Approves 1-for-35 Reverse Stock Split, Reducing Shares to 655K
- Reverse Stock Split Decision: enVVeno Medical's board approved a 1-for-35 reverse stock split effective January 20, 2026, reducing outstanding shares from approximately 22.9 million to about 655,000, aiming to enhance share price and attract investor interest.
- Exchange Arrangement: Post-split, the company's common stock will resume trading on the Nasdaq Capital Market under the existing ticker symbol 'NVNO', indicating a strategic move to improve market perception and liquidity.
- Market Reaction: Following the reverse split announcement, enVVeno Medical's stock price fell 19.69% in premarket trading to $0.2761, reflecting negative market sentiment that could impact investor confidence.
- Shareholder Impact: The reverse split will consolidate every 35 shares into one, which may reduce the number of shares held by shareholders in the short term, but the company aims to improve long-term investment appeal through a higher share price.
Continue Reading
Gold Drops More Than 2%; Cidara Therapeutics Stock Soars
U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones falling 0.44%, while the NASDAQ and S&P 500 rose by 0.59% and 0.27%, respectively. Utilities shares increased slightly, but communication services stocks dropped by 1%.
Notable Company Performances: Spire Inc's shares fell over 2% after reporting larger-than-expected quarterly losses, while Cidara Therapeutics saw a 105% surge in shares following Merck's acquisition announcement.
Commodities Update: Oil prices rose by 1.9% to $59.81, while gold and silver prices fell by 2.2% and 5%, respectively. Copper also saw a decline of 1.1%.
Global Market Trends: European shares declined, with the STOXX 600 down 1.54%, and Asian markets mostly closed lower, highlighted by Japan's Nikkei 225 dropping 1.77%.
Continue Reading